Autosomal Dominant Polycystic Kidney Disease
Conditions
Brief summary
A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Detailed description
This Phase I, randomised, single-blind, placebo-controlled study will assess the safety and tolerability of AZD1613 and characterise the pharmacokinetics (PK) of AZD1613 in participants with autosomal dominant polycystic kidney disease (ADPKD), following subcutaneous (SC) or intravenous (IV) administration. Inclusion of participants receiving placebo is appropriate for benchmarking the safety and tolerability of AZD1613. Furthermore, the safety and PK profile will be evaluated in Chinese participants with ADPKD to assess any potential race effect in this population.
Interventions
DRUGAZD1613 - Part A
Part A - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.
DRUGPlacebo - Part A
Part A - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.
DRUGAZD1613 - Part B
Part B - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.
DRUGPlacebo - Part B
Part B - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study will be single-blinded in order to minimize bias in the collection and evaluation of data during its conduct.
Intervention model description
This is a Phase I, first-in-patient, randomized, single-blind, placebo-controlled study with a sequential MAD design in participants with autosomal dominant polycystic kidney disease (ADPKD). AZD1613 will be administered either subcutaneously or intravenously in up to 5 cohorts.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes * eGFR = 45 to 90 mL/min /1.73m2 * Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg/m2 (inclusive). * Females are to be of non-childbearing potential
Exclusion criteria
* As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study. * Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening. * History of QT prolongation associated with other medications that required discontinuation of that medication. * Congenital long QT syndrome. * History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation/flutter and controlled ventricular rate HR \< 100 bpm can be eligible as judged by the investigator. * Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator. * Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (TEAEs) | From randomization (Day 1) through end of follow-up (up to Day 189 ±3 days) | Number of participants with at least one TEAE and SAE, including events leading to discontinuation or death; coded by system organ class and preferred term. Unit: participants. |
| Change From Baseline in Safety 12-Lead ECG QTcF | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in QT interval corrected using Fridericia's formula (QTcF) measured on single 12-lead safety ECGs. Unit: milliseconds (ms). |
| Change From Baseline in Safety 12-Lead ECG PR Interval | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in PR interval measured on single 12-lead safety ECGs. Unit: milliseconds (ms). |
| Change From Baseline in Safety 12-Lead ECG QRS Duration | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in QRS duration measured on single 12-lead safety ECGs. Unit: milliseconds (ms). |
| Change From Baseline in Heart Rate (12-Lead Safety ECG) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in heart rate measured on single 12-lead safety ECGs. Unit: beats per minute (bpm). |
| Change From Baseline in ALT | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in alanine aminotransferase. Unit: U/L. |
| Change From Baseline in AST | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in aspartate aminotransferase. Unit: U/L. |
| Change From Baseline in Total Bilirubin | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in total bilirubin. Unit: mg/dL. |
| Change From Baseline in Serum Creatinine | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in serum creatinine. Unit: mg/dL. |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR; CKD-EPI 2021) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in eGFR calculated using CKD-EPI 2021. Unit: mL/min/1.73 m². |
| Change From Baseline in INR | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in international normalized ratio- (INR). Unit: unitless. |
| Change From Baseline in Prothrombin Time (PT) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in prothrombin time. Unit: seconds (s). |
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in aPTT. Unit: seconds (s). |
| Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) | Baseline (Day -1) and scheduled visits through Day 189 ±3 days; UACR as triplicate first-morning voids per visit | Change from baseline in UACR (geometric mean of triplicates at each visit). Unit: mg/g. |
| Change From Baseline in Systolic Blood Pressure | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in supine systolic blood pressure. Unit: mmHg. |
| Change From Baseline in Diastolic Blood Pressure | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in supine diastolic blood pressure. Unit: mmHg. |
| Change From Baseline in Heart Rate (Vital Signs) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in supine heart rate. Unit: bpm. |
| Change From Baseline in Body Temperature | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in oral body temperature. Unit: °C. |
| Change From Baseline in Respiratory Rate | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in respiratory rate. Unit: breaths per minute. |
| Change From Baseline in Oxygen Saturation (SpO2) | Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days | Change from baseline in pulse oximetry oxygen saturation. Unit: percent (%). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of AZD1613 | Intensive PK sampling from Day 1 through Day 189 per protocol schedule | Maximum observed serum concentration following subcutaneous or intravenous administration. Unit: µg/mL. |
| Area Under the Concentration-Time Curve to Last Quantifiable Concentration (AUClast) of AZD1613 | Intensive PK sampling from Day 1 through Day 189 per protocol schedule | AUC from time zero to last quantifiable concentration. Unit: h·µg/mL (or day·µg/mL; align with bioanalytical report). |
| Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of AZD1613 | Intensive PK sampling from Day 1 through Day 189 per protocol schedule | AUC from time zero extrapolated to infinity. Unit: h·µg/mL (or day·µg/mL). |
| Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUCtau) of AZD1613 | Over the dosing interval (τ = 28 days) at steady state; sampling through Day 189 | AUC over the dosing interval at steady state. Unit: h·µg/mL (or day·µg/mL). |
| Time to Maximum Observed Serum Concentration (Tmax) of AZD1613 | Intensive PK sampling from Day 1 through Day 189 per protocol schedule | Time to reach Cmax after dosing. Unit: hours (h). |
| Terminal Elimination Half-Life (t½) of AZD1613 | Intensive PK sampling from Day 1 through Day 189 per protocol schedule | Half-life associated with terminal slope (λz) of the concentration-time curve. Unit: hours (h) or days (d). |
| Incidence of Anti-Drug Antibodies (ADA) to AZD1613 | Predose on dosing days and during follow-up through Day 189 ±3 days | Number of participants with ADA-positive response based on validated tiered assay (screen and confirm). Unit: participants. |
| ADA Titer to AZD1613 | Predose on dosing days and during follow-up through Day 189 ±3 days | Titer among confirmed ADA-positive samples. Unit: reciprocal dilution (titer). |
| Change From Baseline in PD Markers of PAPPA-1 Inhibition | Baseline to scheduled post-dose time points through Day 189 ±3 days | Change from baseline in pharmacodynamic marker of PAPPA-1 inhibition. Unit: ng/mL (or assay-specific unit). |
Countries
China, United Kingdom, United States
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed